Vinva Investment Management Ltd Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Vinva Investment Management raised its stake in Regeneron by 31.3% in Q3, buying an additional 2,093 shares to hold 8,775 shares worth about $4.92 million.
• Company insiders sold a total of 5,274 shares valued at roughly $4.14 million over the last three months — including trades by directors Arthur F. Ryan and Bonnie L. Bassler — leaving insiders with 7.02% ownership.
• Wall Street has a consensus rating of Moderate Buy on REGN with a consensus price target of $802.27, after several analysts raised ratings and price objectives.

Vinva Investment Management Ltd raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 31.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,775 shares of the biopharmaceutical company's stock after purchasing an additional 2,093 shares during the quarter. Vinva Investment Management Ltd's holdings in Regeneron Pharmaceuticals were worth $4,921,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Traub Capital Management LLC purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, Berbice Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 60 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company's stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 over the last three months. 7.02% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on REGN. Barclays began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday. They set an "overweight" rating and a $923.00 price objective on the stock. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an "outperform" rating in a report on Thursday, December 4th. Bank of America raised shares of Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and lifted their price target for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. Finally, Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an "equal weight" rating in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $802.27.

Regeneron Pharmaceuticals Stock Down 0.7%

REGN stock opened at $759.82 on Monday. The firm has a market cap of $80.33 billion, a price-to-earnings ratio of 18.28, a PEG ratio of 2.04 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The firm has a fifty day moving average price of $770.81 and a two-hundred day moving average price of $689.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm posted $12.07 EPS. The company's revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is presently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.